3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Leukemia, Myeloid, Acute
127
Precursor Cell Lymphoblastic Leukemia-Lymphoma
45
Myelodysplastic Syndromes
25
Leukemia
25
Burkitt Lymphoma
25
Leukemia, Biphenotypic, Acute
20
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
14
Lymphoma, Mantle-Cell
14
Recurrence
13
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
10
Myeloproliferative Disorders
9
Lymphoma
9
Lymphoma, Non-Hodgkin
8
Leukemia, Myelomonocytic, Chronic
8
Lymphoma, Large B-Cell, Diffuse
7
Down Syndrome
6
Neoplasm, Residual
5
Hodgkin Disease
5
Blast Crisis
5
Sarcoma, Myeloid
4
Lymphoma, T-Cell
4
Leukemia, Monocytic, Acute
4
Hematologic Neoplasms
4
Lymphoma, Follicular
3
Leukemia, Myelomonocytic, Juvenile
3
Leukemia, Myelomonocytic, Acute
3
Leukemia, Myeloid, Accelerated Phase
3
Neoplasms
2
Multiple Myeloma
2
Lymphoma, B-Cell
2
Interventions
Carboplatin
6
pembrolizumab
3
Paclitaxel
3
Observation
3
Capecitabine
3
Azacitidine
3
venetoclax
2
pertuzumab
2
olaparib
2
durvalumab
2
Tretinoin
2
Trastuzumab
2
Standard of Care
2
Oxaliplatin
2
Irinotecan
2
Immunotherapy
2
Chemoradiotherapy
2
130-nm albumin-bound paclitaxel
2
zanidatamab
1
veliparib
1
tucatinib
1
trilaciclib
1
trebananib
1
trastuzumab duocarmazine
1
toripalimab
1
tislelizumab
1
tegafur-gimeracil-oteracil
1
taxane
1
talazoparib
1
tagraxofusp
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Pathologic Complete Response
×
Cytarabine
×
1 year
×
Clear all
NCT04229979
2025-10-01
REGAL
Sellas Life Sciences Group
Phase 3
Active not recruiting
127 enrolled